Form 4: Tenaya Therapeutics Director Receives Stock Option Grant

Director Jeffrey T. Walsh was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Summary

• Director Jeffrey T. Walsh received a grant of 120,000 stock options on May 28, 2026.
• The options have an exercise price of $0.7989 per share.
• The options are scheduled to vest in full on May 28, 2027, or the day before the next annual stockholders meeting, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of Tenaya Therapeutics common stock.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with corporate performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in small-cap clinical-stage biotech companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options on May 28, 2027.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Form 4, Insider Trading, Stock Options, Director Compensation